By Reuters Staff
2 Min Read
BRUSSELS (Reuters) - The European Medicines Agency (EMA) is in the process of offering advice to the developers of the Russian Sputnik V COVID-19 vaccine, but is not currently reviewing it for approval, the agency’s chief said on Tuesday.
Slideshow ( 2 images )
EMA provides scientific advice to drug developers designed to ensure trials are performed efficiently and to the highest standards.
The agency has authorised two vaccines, one developed by Pfizer and BioNTech and another from Moderna, and is expected to clear an AstraZeneca vaccine developed with Oxford University on Friday.
It is also conducting a rolling review of a possible vaccine from Janssen, but with no timetable for its evaluation, EMA Executive Director Emer Cooke said.
EU drugs agency says it is advising makers of Russian vaccine
FILE PHOTO: Exterior of EMA, European Medicines Agency is seen in Amsterdam
BRUSSELS (Reuters) – The European Medicines Agency (EMA) is in the process of offering advice to the developers of the Russian Sputnik V COVID-19 vaccine, but is not currently reviewing it for approval, the agency’s chief said on Tuesday.
EMA provides scientific advice to drug developers designed to ensure trials are performed efficiently and to the highest standards.
The agency has authorised two vaccines, one developed by Pfizer and BioNTech and another from Moderna, and is expected to clear an AstraZeneca vaccine developed with Oxford University on Friday.
By Reuters Staff
1 Min Read
FILE PHOTO: A vial and sryinge are seen in front of a displayed AstraZeneca logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic/Illustration
BERLIN (Reuters) - The European Medicines Agency (EMA) is expected to approve the COVID-19 vaccine developed by AstraZeneca and Oxford University on Friday, a spokesman of German’s health ministry said.
EU officials are due to seek clarification from AstraZeneca executives on unexpected delivery problems on Monday afternoon.
Reporting by Kirsti Knolle, editing by Thomas Escritt